ArticleAntimicrobial agents and chemotherapy1999
Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans.
Article in Antimicrobial agents and chemotherapy, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Brazilian guidelines for the diagnosis and treatment of candidemia and invasive candidiasis in adults and children.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesGuideline
- Pathogenicity Evaluation on Fluconazole-Resistant Candida auris Clade V in Murine Model.Mycopathologia · 2025Article
- In Vitro-In Vivo Correlation of Posaconazole-Amphotericin B Combination againstJournal of fungi (Basel, Switzerland) · 2023Article
- Sustained Release of Antifungal and Antibacterial Agents from Novel Hybrid Degradable Nanofibers for the Treatment of Polymicrobial Osteomyelitis.International journal of molecular sciences · 2023Article
- In Vivo Efficacy of Amphotericin B against FourJournal of fungi (Basel, Switzerland) · 2022Article
- Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations.Journal of fungi (Basel, Switzerland) · 2021Review
- In Vitro Characterization of Twenty-One Antifungal Combinations against Echinocandin-Resistant and -SusceptibleJournal of fungi (Basel, Switzerland) · 2021Article
- Resorbable Beads Provide Extended Release of Antifungal Medication: In Vitro and In Vivo Analyses.Pharmaceutics · 2019Article
- Fluconazole Increases Osmotic Water Transport in Renal Collecting Duct through Effects on Aquaporin-2 Trafficking.Journal of the American Society of Nephrology : JASN · 2019Article
- Article
- Commercial AHAS-inhibiting herbicides are promising drug leads for the treatment of human fungal pathogenic infections.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model.Journal of microbiology (Seoul, Korea) · 2016Article
- Voriconazole-induced inhibition of the fungicidal activity of amphotericin B in Candida strains with reduced susceptibility to voriconazole: an effect not predicted by the MIC value alone.Antimicrobial agents and chemotherapy · 2011Article
- Treatment of invasive candidiasis in immunocompromised pediatric patients.Paediatric drugs · 2008Review
- Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo.Antimicrobial agents and chemotherapy · 2005Article
- Combination treatment of invasive fungal infections.Clinical microbiology reviews · 2005Review
- Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection.Antimicrobial agents and chemotherapy · 2004Article
- In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata.Antimicrobial agents and chemotherapy · 2004Article
- Combination antifungal therapy.Antimicrobial agents and chemotherapy · 2004Review
- Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90.Antimicrobial agents and chemotherapy · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interaction between fluconazole (Flu) and amphotericin B (AmB) was evaluated in a murine model of systemic candidiasis for one Flu-susceptible strain (MIC, 0.5 microg/ml), two strains with intermediate Flu resistance (Flu mid-resistant strains) (MIC, 64 and 128 microg/ml), and one highly Flu-resistant strain (MIC, 512 microg/ml) of Candida albicans. Differences in fungal densities in kidneys of infected mice after 24 h of therapy and in survival rates at 62 days of mice treated with an antifungal drug or a combination of antifungal drugs for 4 days were compared. For the Flu-susceptible and Flu mid-resistant strains, the combination of Flu and AmB was antagonistic, as shown by both quantitative culture results and survival. The interaction was additive for the highly Flu-resistant strain. These results suggest that the combination of Flu and AmB should be used with caution in infections due to fungi that are usually susceptible to both antifungal agents and as empirical antifungal drug therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.